SciClone Pharmaceuticals
Hangzhou, China· Est.
A China-based biopharma company commercializing Zadaxin and developing novel oncology and anti-infective therapies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A China-based biopharma company commercializing Zadaxin and developing novel oncology and anti-infective therapies.
OncologyInfectious DiseaseCardiovascular
Technology Platform
Focus on peptide-based immunomodulation (Thymalfasin) and development of novel chemical entity conjugates for oncology, such as phosphatidylethanolamine-targeted platinum agents.
Opportunities
Growth through lifecycle management of Zadaxin, clinical advancement of novel oncology asset PT-112, and introduction of partnered anti-infectives like meropenem-vaborbactam into the large Chinese market.
Risk Factors
Clinical development risk for PT-112, high competition in Chinese oncology and anti-infective markets, and potential pricing/reimbursement pressures from Chinese healthcare policies.
Competitive Landscape
Competes with large multinational pharma and domestic Chinese biotechs in oncology and infectious diseases; differentiation is based on established commercial footprint with Zadaxin and a niche pipeline of novel conjugates like PT-112.